z-logo
open-access-imgOpen Access
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
Author(s) -
Alina Iovleva,
Mustapha M. Mustapha,
M. Patrick Griffith,
Lauren Komarow,
Courtney Luterbach,
Daniel R. Evans,
Eric Cober,
Sandra S. Richter,
Kirsten Rydell,
César A. Arias,
Jesse T. Jacob,
Robert A. Salata,
Michael J. Satlin,
Darren Wong,
Robert A. Bonomo,
David van Duin,
Vaughn S. Cooper,
Daria Van Tyne,
Yohei Doi
Publication year - 2022
Publication title -
mbio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.562
H-Index - 121
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.02759-21
Subject(s) - acinetobacter baumannii , antimicrobial , microbiology and biotechnology , antibiotic resistance , carbapenem , acinetobacter , drug resistance , medicine , biology , intensive care medicine , virology , pseudomonas aeruginosa , bacteria , antibiotics , genetics
Carbapenem-resistantAcinetobacter baumannii (CRAb ) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CRAb in the United States, clinical CRAb isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom